At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
IONIS DGAT2Rx +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (IONIS-DGAT2Rx, an Antisense Inhibitor of Diacylglycerol Acyltransferase 2) Administered Once-Weekly for 13 Weeks in Adult Patients With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating IONIS DGAT2Rx and Placebo for Hepatic Steatosis. Completed, enrolled 44 participants across 22 sites in 4 countries.
Detailed Summary
The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Steatosis
CountriesCanada, Hungary, Poland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionNov 2018
TodayJul 2026
First PostedNov 7, 2017
Enrollment StartNov 3, 2017
Primary CompletionNov 28, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago
Interventions
IONIS DGAT2Rxdrug
Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
Placebodrug
Saline 0.9%